Home » Stocks » Paratek Pharmaceuticals

Paratek Pharmaceuticals, Inc. (PRTK)

Stock Price: $4.48 USD -0.03 (-0.67%)
Updated Aug 6, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 193.23M
Revenue (ttm) 22.87M
Net Income (ttm) -120.80M
Shares Out 43.13M
EPS (ttm) -3.44
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 6, 2020
Last Price $4.48
Previous Close $4.51
Change ($) -0.03
Change (%) -0.67%
Day's Open 4.52
Day's Range 4.45 - 4.64
Day's Volume 293,519
52-Week Range 2.50 - 6.41

More Stats

Market Cap 193.23M
Enterprise Value 260.70M
Earnings Date (est) Aug 10, 2020
Ex-Dividend Date n/a
Shares Outstanding 43.13M
Float 37.04M
EPS (basic) -3.49
EPS (diluted) -3.44
FCF / Share -3.10
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 3.94M
Short Ratio 6.44
Short % of Float 8.97%
Beta 1.52
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 8.45
PB Ratio n/a
Revenue 22.87M
Operating Income -105.89M
Net Income -120.80M
Free Cash Flow -129.10M
Net Cash -67.47M
Net Cash / Share -1.56
Gross Margin -115.87%
Operating Margin -463.08%
Profit Margin -528.30%
FCF Margin -564.58%
ROA -26.15%
ROE -1,459.30%
ROIC -27.60%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (6)

Buy 5
Overweight 0
Hold 1
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$16.80*
(275.00% upside)
Low
6.00
Current: $4.48
High
34.00
Target: 16.80
*Average 12-month price target from 5 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue16.5417.1212.620.03-4.340.4811.0319.6912.50
Revenue Growth-3.35%35.68%43403.45%--808.37%-95.66%-44.01%57.55%-
Gross Profit13.0617.1212.620.03-4.340.489.6019.6912.50
Operating Income-116-104-85.16-110-73.61-7.80-7.54-11.86-3.76-9.22
Net Income-129-112-89.07-112-70.86-17.84-4.65-12.02-3.88-9.30
Shares Outstanding32.7931.5126.8320.2516.502.530.061.421.131.12
Earnings Per Share-3.93-3.57-3.32-5.51-4.29-7.82-185.13-8.40-3.48-8.28
Operating Cash Flow-134-81.18-78.57-94.10-54.68-18.53-6.36-15.21-5.71-19.55
Capital Expenditures-0.24-0.06-1.12-0.69-0.86---0.04-0.06-0.07
Free Cash Flow-134-81.24-79.69-94.79-55.54-18.53-6.36-15.25-5.77-19.61
Cash & Equivalents21625115212913498.801.2185.4862.5668.17
Total Debt26322959.1938.9719.57-1.35---
Net Cash / Debt-47.1221.6692.7089.8811498.80-0.1485.4862.5668.17
Assets2513001641361461101.2998.0669.1573.81
Liabilities29125381.2264.1444.6814.7435.052.663.4010.00
Book Value-39.6547.5882.4871.5910195.22-11495.3965.7563.81
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Paratek Pharmaceuticals, Inc.
Country United States
Employees 101
CEO Evan Loh

Stock Information

Ticker Symbol PRTK
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: PRTK

Description

Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its lead product candidates include NUZYRA, a once-daily oral and intravenous broad-spectrum antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections caused by susceptible pathogens; and SEYSARA, a tetracycline designed for the treatment of moderate to severe acne vulgaris. The company has license and collaboration agreements with Zai Lab (Shanghai) Co., Ltd. and Allergan plc; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions; and cooperative research and development agreement with the U.S. Army Medical Research Institute of Infectious Diseases to study omadacycline against pathogenic agents causing infectious diseases. Paratek Pharmaceuticals, Inc. was founded in 1996 and is headquartered in Boston, Massachusetts.